All Stories

Nvidia outlines new AI projects in robotic surgery, autonomous imaging

Nvidia outlines new AI projects in robotic surgery, aut...

Mar 21, 2025 0

At its GTC conference in San Jose, Nvidia outlined collaborations with several m...

Speed, Scale, and Success – The Rise of Bispecific Antibodies in Targeted Therapies

Speed, Scale, and Success – The Rise of Bispecific Anti...

Mar 21, 2025 0

Bispecific antibodies are revolutionizing targeted therapies, enabling dual-targ...

Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; Vaxart trims team

Fierce Biotech Layoff Tracker 2025: Elevation eliminate...

Mar 21, 2025 0

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs

Adaptimmune, after bringing cell therapy to market, que...

Mar 21, 2025 0

Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressin...

European countries, universities implement initiatives to attract US researchers amid ‘brutal funding cuts’

European countries, universities implement initiatives ...

Mar 21, 2025 0

As the U.S. cuts federal research funding and infrastructure, European countries...

UPDATE: Director of National Human Genome Research Institute departs in another Trump admin shakeup

UPDATE: Director of National Human Genome Research Inst...

Mar 21, 2025 0

"Eric Green, M.D. Ph.D., is no longer serving as director of NIH’s National Huma...

Vaxart lays off 10% of staff after HHS unexpectedly demands halt to COVID vaccine trial

Vaxart lays off 10% of staff after HHS unexpectedly dem...

Mar 21, 2025 0

Vaxart has laid off 10% of its staff after the U.S. government unexpectedly orde...

UPDATE: Director of NIH's National Human Genome Research Institute departs

UPDATE: Director of NIH's National Human Genome Researc...

Mar 21, 2025 0

"Eric Green, M.D. Ph.D., is no longer serving as director of NIH’s National Huma...

AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts

AstraZeneca details $2.5B investment in China's politic...

Mar 21, 2025 0

AstraZeneca has shown its commitment to China amid investigations into its execu...

Chutes & Ladders—Former FDA deputy joins AI biotech's board

Chutes & Ladders—Former FDA deputy joins AI biotech's b...

Mar 21, 2025 0

About three months after leaving her post as the FDA’s principal deputy commissi...

Eisai's abandoned Enhertu challenger set to live on at BlissBio

Eisai's abandoned Enhertu challenger set to live on at ...

Mar 21, 2025 0

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-d...

MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data

MacroGenics pulls plug on vobra duo ADC after seeing ph...

Mar 21, 2025 0

MacroGenics has made the final decision to abandon work on one of its most advan...

BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeline prioritization

BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeli...

Mar 20, 2025 0

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. ...

British investment firm secures $250M to help fund development of new dementia therapeutics

British investment firm secures $250M to help fund deve...

Mar 20, 2025 0

British investment firm SV Health Investors has secured $250 million to go towar...

Adaptimmune, after bringing cell therapy to market, questions viability and cuts 2 preclinical programs

Adaptimmune, after bringing cell therapy to market, que...

Mar 20, 2025 0

Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressin...

Insulet Type 1 diabetes study shows gains in 3 months after starting first automated insulin pump

Insulet Type 1 diabetes study shows gains in 3 months a...

Mar 20, 2025 0

A randomized study from Insulet of adults and children with Type 1 diabetes foun...

Elevation drops sole clinical-stage ADC over poor phase 1 data, lays off 70% of staff

Elevation drops sole clinical-stage ADC over poor phase...

Mar 20, 2025 0

Elevation is ditching its sole clinical-stage asset in the wake of disappointing...

Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; bit.bio cuts 25% of workforce

Fierce Biotech Layoff Tracker 2025: Elevation eliminate...

Mar 20, 2025 0

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Monte Rosa's broad molecular glue degrader plan comes unstuck, but prostate cancer work continues

Monte Rosa's broad molecular glue degrader plan comes u...

Mar 20, 2025 0

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide ran...

'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up

'Not a cost-cutting exercise': Novo Nordisk CSO explain...

Mar 20, 2025 0

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danis...

Regulatory T-cell therapy calms autoimmune response from gluten-sensitive T cells in mice

Regulatory T-cell therapy calms autoimmune response fro...

Mar 20, 2025 0

For the 80 million people worldwide who have celiac disease, the only treatment ...

BioNTech passes on Autolus’ CD19/CD22 CAR-T amid pipeline prioritization

BioNTech passes on Autolus’ CD19/CD22 CAR-T amid pipeli...

Mar 20, 2025 0

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. ...

Sanofi pays $600M upfront for Dren Bio's bispecific in latest immunology play

Sanofi pays $600M upfront for Dren Bio's bispecific in ...

Mar 20, 2025 0

The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager...

Sanofi pays $600M upfront for Dren Bio’s bispecific in latest immunology play

Sanofi pays $600M upfront for Dren Bio’s bispecific in ...

Mar 20, 2025 0

The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager...

9
10
11
12
13

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.